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CASE STUDY
Uncommon presentation of potential 
medication-related osteonecrosis of the jaw
Seong‑Gon Kim1* , HaeYong Kweon2 and Suk‑Keun Lee3
Abstract 
Background: This article presents a patient with potential atypical medication‑related osteonecrosis of the jaw and 
reviews related literatures.
Case presentation: A 52‑year‑old male showed pain in the left buccal area and had numbness on the left lower 
lip area. He received medications having anti‑angiogenic effect for 4 years. He did not receive irradiation of the jaw 
regions. In histological view, most of the adipocytes were destroyed and disappeared in the scanty vascular mar‑
row tissue, resulting in the replacement of the fatty necrosis with variable sized vacuolated empty spaces. In the 
immunohistochemistry analysis, the infiltrated macrophages into the marrow stromal tissue were strongly positive 
for lysozymes. These findings demonstrate that the presented osteonecrosis underwent a chronic and persistent 
granulomatous inflammatory reaction.
Conclusions: We conclude that the present case might have been caused by anti‑angiogenic drug abuse, affect‑
ing the reduction of the mandibular marrow vascularity and subsequently inducing fatty necrosis and an extensive 
osteolytic change of the mandible.
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Background
Since bisphosphonate-related osteonecrosis of the jaw 
bone was first reported, many reports regarding medica-
tion-related osteonecrosis of the jaw (MRONJ) have fol-
lowed. Most cases are related to dental injury or teeth in 
their onset or pathogenesis, and jaw bone exposure over 
8 weeks is a prerequisite for diagnosis (Khosla et al. 2007; 
Ruggiero et al. 2009). Additionally, MRONJ patients have 
a positive history for anti-angiogenic drugs, but no his-
tory of irradiation (Ruggiero et  al. 2009). Recently, we 
observed a case of osteonecrosis of the jaw bone. Unusu-
ally, the lesion is located below the inferior alveolar canal 
and is not related to a dental lesion. The patient had been 
prescribed medicine for over 3 years for the symptomatic 
treatment of pneumoconiosis. The potential cause for 
osteonecrosis is analyzed in this publication.
Case report
On Apr 16, 2015 a 52-year-old male was referred from 
a local clinic because of a radiolucent lesion in the left 
mandibular angle area. The patient showed pain in the 
left buccal area and had numbness on the left lower lip 
area. He received an operation under general anesthesia 
because of pneumothorax in 1998. He had been diag-
nosed with pneumoconiosis in 2001. Because the symp-
toms of pneumoconiosis were aggravated from 2011, he 
received medications, such as ozagrel, erdostein, acebro-
phyline, and Synatura® (Ahngook Pharm, Seoul, Korea), 
intermittently. Synatura® is an herbal medicine mixed 
with ivy leaf and coptis stalk. From February 2015, he 
received olmesartan (an angiotensin receptor antagonist) 
for the treatment of hypertension. From March 2015, 
he received atrovastatin calcium for the treatment of 
hyperlipidemia. He did not receive irradiation of the jaw 
regions. From a computerized tomogram examination, 
we observed that the lesion was localized in the left first 
and second molar area below the inferior alveolar canal 
(Fig. 1a). The lingual cortex adjacent to the lesion showed 
an erosive change (Fig.  1b). Based on the radiologic 
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findings, the lesion was primarily diagnosed as Stafne’s 
bone cyst.
An excisional biopsy of the left mandibular body was 
performed using the submandibular approach. Yel-
low colored semi-solid materials were removed from 
the bone marrow cavity (Fig. 2a). The lesion was poorly 
encapsulated, and the surrounding cortical bone had 
become thin but appeared to be intact (Fig.  2b). After 
removing the necrotic tissue, the wound was closed layer 
by layer. The removed specimen was sent for pathological 
examination. The removed specimen was fixed in 10  % 
neutral formalin and sectioned at a thickness of 4  μm. 
The microsections were routinely stained with hematoxy-
lin and eosin (HE), and we also performed immunohis-
tochemical (IHC) staining using anti-sera of lysozyme 
(DAKO, Glostrup, Denmark), matrix metalloprotease-1 
(MMP-1, Santa Cruz Biotech, Santa Cruz, CA, USA), 
MMP-2 (Santa Cruz Biotech), MMP-3 (Santa Cruz Bio-
tech), hypoxia inducible protein alpha (HIFα; Abcam, 
Cambridge, UK), vascular endothelial cell growth fac-
tor (VEGF; Abcam), osteoprotegerin (OPG; Santa Cruz 
Biotech), and the receptor activator of nuclear factor-
kappa B ligand (RANKL; Santa Cruz Biotech). IHC stain-
ing was performed using the indirect triple sandwich 
method. The use of the present biopsy specimen was 
filed in the Department of Oral Pathology, Gangneung-
Wonju National University Dental Hospital, and was 
approved by our institutional review board (IRB2015-7). 
The sections of the embedded specimens were stained 
with HE. The specimens contained inflammatory cells 
Fig. 1 Computerized tomogram findings. a The osteolytic lesion was localized in the left first and second molar area below the inferior alveolar 
canal. b The lingual cortex adjacent to the lesion showed erosive changes
Fig. 2 Intra‑operative views. a The yellow colored semi‑solid materials were filled with a bone marrow cavity. b After removing the osteolytic lesion, 
the surrounding cortical bone was thin but appeared intact
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and fibroblastic cells. Variable sized woven bone was 
observed with a cholesterol cleft appearance (Fig.  3a). 
The marrow stromal tissue was diffusely fibrosed and 
filled with fatty bubble-like materials and was infiltrated 
with a large number of macrophages (Fig.  3b). Most of 
the adipocytes were destroyed and disappeared, result-
ing in the replacement of the fatty necrosis with variable 
sized vacuolated empty spaces. There also appeared to be 
several foci of the cholesterol slits, where fatty materials 
were also removed during the histological procedures 
(Fig. 3c). Stromal fibrosis increased in areas lacking vas-
cular channels and advanced to the osteolytic trabecular 
bones, which showed irregular and rudimentary bony 
trabeculae with no signs of osteoid deposition and bis-
phosphonate-related multiple reversal lines (Fig. 3d).
In the immunohistochemistry analysis, the mar-
row stromal tissue was weakly positive for MMPs and 
the infiltrated macrophages were strongly positive for 
lysozymes (Fig. 4). Some marrow cells near the osteolytic 
trabecular bones were strongly positive for RANKL and 
OPG, and the stromal fibrous tissue was consistently pos-
itive for HIFα, but rarely positive for VEGF.
After surgery, the patient was advised to stop taking 
Synatura® and olmesartan, which are anti-angiogenic 
drugs. The patient’s symptoms disappeared during fol-
low-up and bone healing was uneventful at 5  months 
postoperatively (Fig. 5). The patient was followed up for 
9  months postoperatively. No event occurred during 
follow-up.
Discussion
Medication-related osteonecrosis of the jaw is frequently 
observed in the jaw bone (Khosla et  al. 2007; Ruggi-
ero et  al. 2009). The drugs known to most commonly 
induce osteonecrosis are bisphosphonate (Abd-Alhaseeb 
et  al. 2014; Balli et  al. 2014) and denosumab (Sivolella 
et  al. 2013). According to the patient’s medication his-
tory, the prescription period of anti-hypertension and 
Fig. 3 The hematoxylin and eosin staining view of the lesion. a Variable‑sized woven bone was observed with a cholesterol cleft appearance 
under low magnification (bar 100 µm). b Under high magnification, the marrow stromal tissue was diffusely fibrosed and filled with fatty bubble‑
like materials, accompanied by the infiltration of many macrophages (bar 20 µm). c There also appeared to be several foci of the cholesterol slits 
(bar 50 µm). d The stromal fibrosis increased in the absence of vascular channels and advanced to the osteolytic trabecular bones, which showed 
irregular and rudimentary bony trabeculae with no signs of osteoid deposition (bar 50 µm)
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anti-hyperlipidemia drugs was less than 2 months. There-
fore, both drugs may have potentiated the progress of the 
osteonecrosis, but did not induce osteonecrosis in this 
patient. As the patient has pneumoconiosis, the bone loss 
of the mandible might be due to the patient’s systemic 
disease. As the severity of pneumoconiosis increases, the 
occurrence of bone loss is significantly higher (Li et  al. 
2012). However, other bones did not display osteoporo-
sis. In addition, pneumoconiosis-related jawbone necro-
sis has not been reported before. Thus, the observed jaw 
bone necrosis might be due to the medications that were 
used.
The patient’s recent use of atorvastatin increased 
VEGF expression in the periodontium (Balli et al. 2014). 
Four different types of drugs had been prescribed to 
the patient over 3  years. Among them, we could not 
find any reference suggesting that ozagrel, erdostein, 
or acebrophyline might induce osteonecrosis or anti-
angiogenesis. Synatura®is produced by a Korean phar-
macologic company and is a type of herbal medicine. 
Synatura® is a mixture of ivy leaf extract and coptis stalk 
extract. One active component of the coptis stalk is ber-
berine (Min et  al. 2006). Berberine has anti-angiogenic 
activity via suppression of VEGF expression (Hamsa and 
Kuttan 2012; Jie et al. 2011). Drugs with anti-angiogenic 
activity, such as bisphosphonates, may induce osteone-
crosis of the jaw bone (Khosla et al. 2007; Ruggiero et al. 
2009; Sivolella et  al. 2013). In addition, the olmesartan 
that the patient took from February 2015 also has an anti-
angiogenic effect (Abd-Alhaseeb et  al. 2014). Accord-
ingly, the observed osteonecrosis of the jaw might be 
caused by the combined effect of multiple drugs.
Contrast to the bisphosphonate-related osteonecrosis 
of the jaw, the present case showed that the osteolytic 
Fig. 4 An immunohistochemistry view of the lesion without counterstain. a Matrix metalloproteinase (MMP)‑1. b MMP‑2. c MMP‑3. d Lysozyme. e 
Receptor activator of nuclear factor‑kappaB ligand (RANKL). f Osteoprotegerin (OPG). g Hypoxia inducible protein alpha (HIFα). h Vascular endothe‑
lial growth factor (VEGF)
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trabecular bones were scattered in the periphery of the 
main lesion and became rudimentay in shape (Fig. 3). In 
addition, osteolytic lesion was not associated with dental 
lesion (Fig. 1). Typical MRONJ has been associated with 
dental lesion or dental procedure (Katsarelis et al. 2015; 
Chandra et  al. 2009). Most of osteocytes in the lacuna 
spaces were still vivid, rarely resulted in bony sequen-
strum (Fig. 3). The marrow stromal tissue had extremely 
low vascularity and diffuse fatty necrosis, resulting in the 
formation of many vacuolated empty spaces and cho-
lesterol slits (Fig.  3). The infiltrated macrophages were 
strongly positive for lysozymes, but did not produce an 
exudative inflammatory reaction (Fig. 4). Unlike typical 
MRONJ, as the necrotic jaw bone was not associated 
with bacterial infection, a severe inflammatory reaction 
was not observed. The stromal fibrous tissue was gradu-
ally degenerated with low expressions of MMPs (Fig. 4), 
but showed no evidence of reparative granulation tis-
sue (Fig. 3). Therefore, we hypothesized that the stromal 
fibrous tissue was sclerosed retrogressively and lost its 
osteogenic properties. However, some stromal cells near 
the resorbing trabecular bones showed strong immu-
noreactions to RANKL and OPG (Fig.  4). This finding 
might indicate that the bone marrow was continuously 
modified by RANKL osteoclastic activity, but was not 
adequately replaced by OPG osteogenic activity due to 
the severe degeneration of the stromal fibroblasts. These 
findings demonstrate that the presented osteonecro-
sis underwent a chronic and persistent granulomatous 
inflammatory reaction (Jang et  al. 2015). Additionally, 
the strong positive reaction of HIFα might indicate that 
the marrow stromal tissue was in a hypoxic condition, 
but this condition was not accompanied by de novo 
angiogenesis because of the sparse VEGF expression 
(Fig. 4).
Most of reported MRONJ cases have a history of dental 
procedure and spontaneous MRONJ cases also have been 
rarely reported (Chandra et al. 2009). Presented case was 
also developed MRONJ spontaneously. Though bisphos-
phonate has been mostly known to induce MRONJ, other 
inhibitors of angiogenesis can be implicated in isolated 
MRONJ (Pakosch et al. 2013). When MRONJ is involved 
the inferior alveolar nerve, the lesion may cause a pain-
ful neuropathy (Zadik et  al. 2012; Kim et  al. 2016). The 
lesion of our case was also involved the inferior alveo-
lar nerve, causing pain. The limitation of our study was 
that 9  months of follow-up was not enough to demon-
strate the relation between drug holiday and resolution of 
the lesion. A follow-up of 1–2 years of the present case 
without recurrence and further drug holiday might be 
needed.
Conclusions
We conclude that the present case might have been 
caused by anti-angiogenic drug abuse, affecting the 
reduction of the mandibular marrow vascularity and sub-
sequently inducing fatty necrosis and an extensive osteo-
lytic change of the mandible. The localized lesion was 
found in the mandibular body without any dental lesion 
or bacterial infection, which are not typical of ordinary 
MRONJ.
Patient consent
The patient has given his consent for the use of his per-
sonal and medical information for this case report.
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Fig. 5 Postoperative panoramic radiography. The bone healing was evident in the left mandibular notch area at 5 months postoperatively
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factor; OPGO: steoprotegerin; RANKL: the receptor activator of nuclear factor‑
kappa B ligand.
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